NCT00116688View on ClinicalTrials.gov

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
ThrombocytopeniaIdiopathic Thrombocytopenic Purpura
Interventions
BIOLOGICAL

Romiplostim

Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY